Vilin Bio Med

Why is Vilin Bio Med Ltd falling/rising?

As of 10-Jun, Vilin Bio Med Ltd's stock price is Rs. 48.00, down 1.44% despite reaching a new high of Rs. 54.4 earlier. The stock shows a positive long-term trend but has seen decreased investor participation and underperformed its sector.

As of 10-Jun, Vilin Bio Med Ltd's stock price is currently at Rs. 48.00, reflecting a decrease of Rs. 0.7, or 1.44%. Despite hitting a new 52-week and all-time high of Rs. 54.4 earlier today, the stock has underperformed its sector by 3.24%. Additionally, there has been a notable decline in investor participation, with the delivery volume dropping by 16.67% compared to the 5-day average. However, it is important to note that the stock is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a generally positive trend in its longer-term performance. The liquidity remains adequate for trading, as it is based on 2% of the 5-day average traded value. Overall, the combination of hitting a high but experiencing a drop in price and investor participation contributes to the current decline in the stock's price.

What does Vilin Bio Med do?

Vilin Bio Med Ltd is a micro-cap pharmaceutical company focused on producing tablets, capsules, and dry syrups, with over 1000 drug approvals in various therapeutic areas since its inception in 2005. Its current market cap is INR 81 Cr, with a P/E ratio of 38.00 and a debt-equity ratio of 0.11.

Overview: <BR>Vilin Bio Med Ltd is a micro-cap company operating in the Pharmaceuticals & Biotechnology industry, focusing on the production of pharmaceutical products, including tablets, capsules, and dry syrups.<BR><BR>History: <BR>Vilin Bio Med Limited was incorporated on June 29, 2005, and commenced business on July 11, 2005. The company began its first commercial production in 2006 and expanded its facilities in 2007. By 2010, it had acquired more than 1000 drug approvals in various therapeutic areas, including diabetes, neurology, and cardiology.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: N/A <BR>Market-cap value: INR 81 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 38.00 <BR>Industry P/E: N/A <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.11 <BR>Return on Equity: 0.95% <BR>Price-to-Book: 3.39 <BR><BR>Contact Details: <BR>Registrar Address: Not available. <BR>Phone: Not available. <BR>Email: Not available. <BR>Website: Not available.

Which are the latest news on Vilin Bio Med?

How has been the historical performance of Vilin Bio Med?

Vilin Bio Med's historical performance shows fluctuating sales growth, peaking at INR 15.80 crore in March 2024, but facing rising raw material costs and declining profits, with net profit after tax dropping to INR 0.22 crore by March 2025. Despite a decrease in total liabilities, the company has struggled with negative cash flow from operations.

Answer:<BR>The historical performance of Vilin Bio Med shows a fluctuating trend in key financial metrics over the past five years.<BR><BR>Breakdown:<BR>Vilin Bio Med's net sales have shown a general increase from INR 11.21 crore in March 2022 to INR 15.80 crore in March 2024, before slightly declining to INR 14.81 crore in March 2025. The total operating income followed a similar trend, peaking in March 2024. However, the raw material costs have risen significantly, from INR 9.06 crore in March 2021 to INR 13.47 crore in March 2025, impacting the operating profit, which decreased from INR 2.59 crore in March 2023 to INR 1.25 crore in March 2025. Profit before tax also declined from INR 1.78 crore in March 2023 to INR 0.31 crore in March 2025, while profit after tax dropped from INR 1.25 crore in March 2023 to INR 0.22 crore in March 2025. The company's total liabilities decreased from INR 32.40 crore in March 2024 to INR 27.73 crore in March 2025, with a notable reduction in short-term borrowings. Cash flow from operating activities has remained negative, with a net cash outflow of INR 5 crore in March 2025. Overall, while Vilin Bio Med has seen growth in sales and income, rising costs and declining profits indicate challenges in maintaining profitability.

Is Vilin Bio Med overvalued or undervalued?

As of September 23, 2025, Vilin Bio Med is considered very expensive with a PE ratio of 35.50, significantly higher than peers like Sun Pharma and Cipla, despite outperforming the Sensex with a 41.27% return over the past year.

As of 23 September 2025, the valuation grade for Vilin Bio Med has moved from expensive to very expensive, indicating a significant increase in perceived overvaluation. The company is currently assessed as overvalued, with a PE ratio of 35.50, an EV to EBIT of 38.02, and a PEG ratio of 0.95. These metrics suggest that the stock is trading at a premium compared to its earnings growth potential.<BR><BR>In comparison to its peers, Vilin Bio Med's PE ratio is higher than Sun Pharma's 34.11 and significantly above Cipla's more attractive 22.93. Additionally, while Divi's Lab shows a very expensive valuation with a PE of 69.64, it highlights the disparity within the sector. Notably, Vilin Bio Med has outperformed the Sensex over the past year with a return of 41.27%, contrasting with the Sensex's decline of 2.97%. This performance, however, does not mitigate the concerns regarding its current valuation levels.

How big is Vilin Bio Med?

As of 23rd July, Vilin Bio Med Ltd has a market capitalization of 35.00 Cr, classifying it as a Micro Cap company. There is no available financial data for Net Sales or Net Profit for the latest four quarters.

As of 23rd July, <BR><BR>Market Cap: Vilin Bio Med Ltd has a market capitalization of 35.00 Cr, which classifies it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for Net Sales or Net Profit for the latest four quarters.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2024, with Shareholder's Funds amounting to 22.84 Cr and Total Assets valued at 32.40 Cr.

Who are the top shareholders of the Vilin Bio Med?

The top shareholders of Vilin Bio Med are Venkata Bhagi Rao Sadhanala with 32.79%, followed by public shareholder Percy Homi Italia at 4.29%, and individual investors holding a total of 34.18%. There are no holdings by mutual funds or foreign institutional investors.

The top shareholders of Vilin Bio Med include the promoters, with Venkata Bhagi Rao Sadhanala holding the largest share at 32.79%. The highest public shareholder is Percy Homi Italia, who owns 4.29%. Additionally, individual investors collectively hold 34.18% of the company's shares. There are currently no holdings by mutual funds or foreign institutional investors (FIIs).

Who are the peers of the Vilin Bio Med?

Vilin Bio Med's peers include Mono Pharmacare, Vineet Laborator, Guj. Terce Labs., Veerhealth Care, Shree Ganesh Bio, Genesis IBRC, ANG Lifesciences, Chandra Bhagat, and Phaarmasia. Vilin Bio Med has the highest 1-year return at 34.25%, while Vineet Laborator has the lowest at -51.27%.

Peers: The peers of Vilin Bio Med are Mono Pharmacare, Vineet Laborator, Guj. Terce Labs., Veerhealth Care, Shree Ganesh Bio, Genesis IBRC, ANG Lifesciences, Chandra Bhagat, and Phaarmasia.<BR><BR>Quality Snapshot: Below Average management risk is observed at Mono Pharmacare, Vilin Bio Med, Veerhealth Care, Shree Ganesh Bio, ANG Lifesciences, Chandra Bhagat, and Phaarmasia, while Average management risk is found at Vineet Laborator and Guj. Terce Labs. Growth is rated as Good at Veerhealth Care and Shree Ganesh Bio, while it is Below Average at Vilin Bio Med, Mono Pharmacare, Vineet Laborator, ANG Lifesciences, Chandra Bhagat, and Phaarmasia, and Average at Guj. Terce Labs. Capital Structure is rated as Good at Veerhealth Care and Shree Ganesh Bio, while it is Below Average at Vilin Bio Med, Mono Pharmacare, Vineet Laborator, Guj. Terce Labs., ANG Lifesciences, Chandra Bhagat, and Phaarmasia.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Vilin Bio Med at 34.25%, while the peer with the lowest 1-year return is Vineet Laborator at -51.27%. Compared to its peers, Vilin Bio Med's return is significantly higher. Additionally, Vineet Laborator and ANG Lifesciences have negative six-month returns.

What is the technical trend for Vilin Bio Med?

As of June 3, 2025, Vilin Bio Med's technical trend is mildly bullish, supported by a bullish weekly MACD and Bollinger Bands, despite bearish signals from the RSI and Dow Theory.

As of 3 June 2025, the technical trend for Vilin Bio Med has changed from bullish to mildly bullish. The weekly MACD remains bullish, while the RSI is bearish, indicating some weakness in momentum. The Bollinger Bands are bullish on both weekly and monthly time frames, supporting the mildly bullish stance. Daily moving averages are also bullish, suggesting short-term strength. However, Dow Theory indicates bearish trends on both weekly and monthly levels, which could be a concern. The On-Balance Volume (OBV) shows a mildly bullish signal weekly but is mildly bearish monthly, adding to the mixed signals. Overall, the current technical stance is mildly bullish, driven primarily by the weekly MACD and Bollinger Bands, despite bearish signals from the RSI and Dow Theory.

When is the next results date for Vilin Bio Med?

No Upcoming Board Meetings

Has Vilin Bio Med declared dividend?

No Dividend History Available